ImmunoPET Imaging of B-cell Lymphoma Using 124I-anti-CD20 ScFv Dimers (diabodies)

Overview

Journal Protein Eng Des Sel

Publisher Oxford University Press

Specialties Biochemistry
Biotechnology

Date 2010 Jan 8

PMID 20053640

Citations 22

Authors

Tove Olafsen

Shannon J Sirk

David J Betting

Vania E Kenanova

Karl B Bauer

Waldemar Ladno

Andrew A Raubitschek

John M Timmerman

Anna M Wu

Affiliations

Soon will be listed here.

Abstract

Rapid clearing engineered antibody fragments for immunoPET promise high sensitivity at early time points. Here, tumor targeting of anti-CD20 diabodies (scFv dimers) for detection of low-grade B-cell lymphomas were evaluated. In addition, the effect of linker length on oligomerization of the diabody was investigated. Four rituximab scFv variants in the V(L)-V(H) orientation with different linker lengths between the V domains (scFv-1, scFv-3, scFv-5, scFv-8), plus the scFv-5 with a C-terminal cysteine (Cys-Db) for site-specific modification were generated. The scFv-8 and Cys-Db were radioiodinated with (124)I for PET imaging, and biodistribution of (131)I-Cys-Db was carried out at 2, 4 10 and 20 h. The five anti-CD20 scFv variants were expressed as fully functional dimers. Shortening the linker to three or one residue did not produce higher order of multimers. Both (124)I-labeled scFv-8 and Cys-Db exhibited similar tumor targeting at 8 h post injection, with significantly higher uptakes than in control tumors (P < 0.05). At 20 h, less than 1% ID/g of (131)I-labeled Cys-Db was present in tumors and tissues. Specific tumor targeting and high contrast images were achieved with the anti-CD20 diabodies. These agents extend the repertoire of reagents that can potentially be used to improve detection of low-grade lymphomas.

Citing Articles

Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.

van der Geest K, Sandovici M, Nienhuis P, Slart R, Heeringa P, Brouwer E Front Med (Lausanne). 2022; 9:902155.

PMID: 35733858 PMC: 9207253. DOI: 10.3389/fmed.2022.902155.

Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.

Kumar K, Ghosh A Molecules. 2021; 26(2).

PMID: 33466827 PMC: 7830191. DOI: 10.3390/molecules26020414.

Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications.

Fu R, Carroll L, Yahioglu G, Aboagye E, Miller P ChemMedChem. 2018; 13(23):2466-2478.

PMID: 30246488 PMC: 6587488. DOI: 10.1002/cmdc.201800624.

The Immunoimaging Toolbox.

Mayer A, Gambhir S J Nucl Med. 2018; 59(8):1174-1182.

PMID: 29794226 PMC: 6071502. DOI: 10.2967/jnumed.116.185967.

ImmunoPET of Malignant and Normal B Cells with Zr- and I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization .

Zettlitz K, Tavare R, Knowles S, Steward K, Timmerman J, Wu A Clin Cancer Res. 2017; 23(23):7242-7252.

PMID: 28928164 PMC: 5880625. DOI: 10.1158/1078-0432.CCR-17-0855.

References

Berk D, Yuan F, Leunig M, Jain R . Direct in vivo measurement of targeted binding in a human tumor xenograft. Proc Natl Acad Sci U S A. 1997; 94(5):1785-90. PMC: 19994. DOI: 10.1073/pnas.94.5.1785. View

Leyton J, Olafsen T, Sherman M, Bauer K, Aghajanian P, Reiter R . Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel. 2008; 22(3):209-16. PMC: 2644405. DOI: 10.1093/protein/gzn055. View

Sirk S, Olafsen T, Barat B, Bauer K, Wu A . Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2. Bioconjug Chem. 2008; 19(12):2527-34. PMC: 2668938. DOI: 10.1021/bc800113v. View

Arndt K, Muller K, Pluckthun A . Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry. 1998; 37(37):12918-26. DOI: 10.1021/bi9810407. View

Wu A, Senter P . Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005; 23(9):1137-46. DOI: 10.1038/nbt1141. View

Huston J, Levinson D, Tai M, Novotny J, Margolies M, Ridge R . Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988; 85(16):5879-83. PMC: 281868. DOI: 10.1073/pnas.85.16.5879. View

Worn A, Pluckthun A . Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Biochemistry. 1999; 38(27):8739-50. DOI: 10.1021/bi9902079. View

Bergman Y, Haimovich J . Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol. 1977; 7(7):413-7. DOI: 10.1002/eji.1830070702. View

Adams G, Schier R, McCALL A, Crawford R, Wolf E, Weiner L . Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer. 1998; 77(9):1405-12. PMC: 2150193. DOI: 10.1038/bjc.1998.233. View

10.

Olafsen T, Kenanova V, Wu A . Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc. 2007; 1(4):2048-60. DOI: 10.1038/nprot.2006.322. View

11.

Yazaki P, Wu A, Tsai S, Williams L, Ikler D, Wong J . Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem. 2001; 12(2):220-8. DOI: 10.1021/bc000092h. View

12.

Olafsen T, Cheung C, Yazaki P, Li L, Sundaresan G, Gambhir S . Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel. 2004; 17(1):21-7. PMC: 4154813. DOI: 10.1093/protein/gzh009. View

13.

Dolezal O, Pearce L, Lawrence L, McCoy A, Hudson P, Kortt A . ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. Protein Eng. 2000; 13(8):565-74. DOI: 10.1093/protein/13.8.565. View

14.

Bird R, HARDMAN K, Jacobson J, Johnson S, Kaufman B, Lee S . Single-chain antigen-binding proteins. Science. 1988; 242(4877):423-6. DOI: 10.1126/science.3140379. View

15.

Sundaresan G, Yazaki P, Shively J, Finn R, Larson S, Raubitschek A . 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med. 2003; 44(12):1962-9. PMC: 4167879. View

16.

Kenanova V, Olafsen T, Crow D, Sundaresan G, Subbarayan M, Carter N . Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005; 65(2):622-31. PMC: 4154799. View

17.

Robinson M, Doss M, Shaller C, Narayanan D, Marks J, Adler L . Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005; 65(4):1471-8. DOI: 10.1158/0008-5472.CAN-04-2008. View

18.

Li L, Olafsen T, Anderson A, Wu A, Raubitschek A, Shively J . Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. Bioconjug Chem. 2002; 13(5):985-95. DOI: 10.1021/bc025565u. View

19.

Olafsen T, Betting D, Kenanova V, Salazar F, Clarke P, Said J . Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med. 2009; 50(9):1500-8. PMC: 2852538. DOI: 10.2967/jnumed.108.060426. View

20.

Adams G, McCartney J, Tai M, Oppermann H, Huston J, Stafford 3rd W . Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 1993; 53(17):4026-34. View